Ep76: Otello Stampacchia on Becoming a Biotech VC

Episode Summary

Executive Summary: Luke Timmerman interviews Omega Funds founder Otello Stampacchia about his path from a science-focused upbringing in Italy to biotech investing, the founding and evolution of Omega, and why he believes the current era is exceptional for life sciences. The conversation covers his education, career pivots, investing philosophy centered on approved products and patient impact, lessons from market cycles, COVID-era changes in science and healthcare, and the role of luck, preparation, and education in success.

Main Topics: Early life and education in Italy (Priority: 5/5): Stampacchia describes growing up in Puglia, his rigorous Italian high school education, key teachers who shaped his thinking, and how early exposure to genetics redirected him from physics toward biology. Career path from science to finance (Priority: 5/5): He explains how PhD training in Geneva exposed him to biotech investing, leading to consulting work, Goldman Sachs, and eventually a move into asset management and venture investing. Founding Omega Funds and investment strategy (Priority: 5/5): Stampacchia recounts launching Omega in 2004 from Geneva with a small first fund, then building a strategy around late-stage/product-focused biotech and secondary investing before expanding into broader venture. Why the current biotech era is unusually strong (Priority: 5/5): He argues that capital availability, technological advances, and a deeper management talent pool have aligned to make this one of the best periods ever for life sciences investment. COVID-19 and lasting changes to science and healthcare (Priority: 4/5): The discussion explores how the pandemic accelerated telemedicine, remote trials, diagnostics, surveillance, and a more resilient healthcare model, while also elevating the strategic value of basic research. Luck, education, and opportunity (Priority: 4/5): Stampacchia closes with a reflection that luck can be improved through education, networks, recognition of opportunities, and the ability to act on them.

Key Arguments: A strong scientific foundation and critical thinking skills, built early in life, can be decisive in a biotech investor’s career. Biotech investing rewards deep domain knowledge and patience; the best outcomes come from products that reach patients, not just financial engineering. Market downturns can create the best entry points for returns, but only if firms have fresh capital and the discipline to act. The biotech talent base has widened since the early 2010s, making company building and execution much stronger than in prior cycles. The pandemic accelerated adoption of telemedicine, remote trials, diagnostics, and surveillance, and these changes are likely durable. Basic research is strategically important to national competitiveness and should be funded more robustly, especially by the U.S. Luck is not purely random; education, relationships, and preparedness increase the odds of recognizing and acting on opportunity.

Data Points: Omega Funds founding year: 2004 - Stampacchia explains when he started Omega in Geneva. Omega fund stage: Fund 6 - Introductory description of Omega’s current fund progression. Assets under management: $1 billion - Luke describes Omega as having about a billion dollars under management. Countries/regions invested in: American, European - Omega invests across geographies, not just one market. Therapeutic areas: Oncology, immunology, rare disease - Examples of the company types Omega backs. Italian high school finish age: 18 - Stampacchia describes the Italian education system and his own timeline. PhD duration: 5 years - He notes Geneva had a five-year PhD program. Initial firm size: $50–60 million - Omega’s first vehicle was small and largely managed by him personally. Investment count: 37 companies acquired; 27 companies public - Stampacchia cites portfolio outcomes as a proxy for success. Most recent fund raised: $430+ million - He notes the December fundraise for Omega’s latest vehicle. U.S. NIH funding: $30-something billion annually - Used to argue basic research is underfunded relative to national priorities. U.S. military spending: $740 billion annually - Comparison used to emphasize how small NIH funding is relative to defense spending. Healthcare strategy size at Alpinvest: Tens of billions of euros - He describes the scale of the fund of funds where he worked in Amsterdam. Time at Goldman Sachs: A few years - He says he spent several years in investment banking before moving on.

Pivotal Quotes: "you don't write because you want to say something. You write because you have something to say" — Otello Stampacchia: Describing how Luke’s invitation prompted him to write early COVID commentary. "the luck favors the prepared mind" — Otello Stampacchia: His explanation of why preparation mattered in his career and investing approach. "this is the most exciting time to be investing in life sciences in a generation" — Otello Stampacchia: His view of the current biotech environment after raising Omega’s latest fund.

Implications: Listeners should see biotech as a discipline where scientific depth, timing, and relationship-building matter as much as capital. For the industry, the episode suggests the next wave of winners will come from product-focused teams, better-funded science, and more resilient healthcare systems.